GE HealthCare and Stryker Valuation Gap Prompts Relative Value Analysis

A significant valuation gap has opened between GE HealthCare Technologies (GEHC) and Stryker Corp. (SYK), two major players in the same healthcare equipment sector. According to an analysis by Investing.com, the stark difference in their trading multiples has prompted a closer look at a relative value thesis, weighing Stryker's premium quality against GE HealthCare's discounted price.

The Valuation Disparity

The core of the analysis highlights that GE HealthCare trades at a substantial discount to Stryker across several key metrics, despite both companies being subject to similar hospital budget cycles. The market appears to be pricing in what the source calls "spin-off skepticism" for GEHC, which separated from General Electric three years ago.

Key valuation metrics from the analysis include:

• Trailing P/E Ratio: GEHC at 14.5x vs. SYK at 29.6x
• Forward P/E Ratio: GEHC at 12.9x vs. SYK at 18.6x
• EV/EBITDA: GEHC at 10.5x vs. SYK at 16.6x
• Free Cash Flow Yield: GEHC at 5.5% vs. SYK at 4.3%

Stryker's Premium Quality

Stryker's higher valuation is supported by superior financial health and growth metrics. The company boasts a perfect Piotroski Score of 9, indicating exceptional financial strength, and commands higher pricing power with gross margins of approximately 65% compared to GEHC's 40%.

Furthermore, Stryker's historical and projected growth is more robust, with a revenue compound annual growth rate (CAGR) of around 10% from 2021-2025, versus about 4% for GEHC. The analysis notes that while Stryker is clearly a higher-quality operator, the key question for investors is whether the quality justifies an earnings multiple that is roughly double that of its peer.

Ad

The Case for GE HealthCare Convergence

Conversely, the investment case for GE HealthCare centers on its compelling valuation and improving fundamentals. The company's 5.5% free cash flow yield is superior to Stryker's, and management has signaled confidence through aggressive share buybacks and three consecutive dividend increases.

While GEHC has higher debt-to-equity and has seen recent downward earnings revisions from analysts, the analysis suggests its debt structure is a manageable artifact of its spin-off. The primary risk identified is a potential deterioration in earnings that is not yet reflected in financial results.

Market Implications

This valuation divergence has led to analysis of a market-neutral pairs trade—a strategy that goes long on the undervalued asset (GEHC) and short on the overvalued one (SYK). Such a trade aims to profit from the convergence of their valuations, independent of the broader market's direction.

Potential catalysts that could narrow the spread include a GEHC earnings beat that triggers a re-rating, any disappointment in Stryker's surgical volumes, or a broader market rotation from growth-oriented stocks like Stryker to value names like GE HealthCare.